All In Biotech

Drug Trial Radar · NCT05836753

Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy

Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy: A Phase II, Randomized, Multicenter, Double-blind, Single Dose, Placebo-controlled Parallel Trial

Last checked: Nov 20, 2026Latest source record: Jul 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

May 7, 2023

Primary completion

Nov 2023

Study completion Dec 2023

Sponsor

Lead sponsor
Beijing Tiantan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Neurodawn Pharmaceutical Co., Ltd.
First posted
May 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study was to evaluate the efficacy and safety of Sarecycline versus placebo in the treatment of microcirculation dysfunction after reperfusion therapy in patients with large vessel occlusion stroke.

Conditions

  • Ischemic Stroke, Acute

Interventions

  • Sarecycline TabletDrug

    Each tablet contained 100 mg of Sarecycline.

  • Placebo tablets of Sarecycline tabletsDrug

    Each tablet contained 0 mg of Sarecycline.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes of NIHSS score between baseline and at 7 days after randomization.Time frame: at 7 days after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tiantan Hospital

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.